KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) Restructuring Costs (2016 - 2025)

Boston Scientific (BSX) has disclosed Restructuring Costs for 17 consecutive years, with $109.0 million as the latest value for Q4 2025.

  • Quarterly Restructuring Costs rose 1008.33% to $109.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $194.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $194.0 million for FY2025, N/A changed from the prior year.
  • Restructuring Costs hit $109.0 million in Q4 2025 for Boston Scientific, up from -$8.0 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $131.0 million in Q4 2022 to a low of -$262.0 million in Q4 2021.
  • Historically, Restructuring Costs has averaged $3.6 million across 5 years, with a median of $8.0 million in 2024.
  • Biggest five-year swings in Restructuring Costs: tumbled 217.49% in 2021 and later skyrocketed 8200.0% in 2025.
  • Year by year, Restructuring Costs stood at -$262.0 million in 2021, then soared by 150.0% to $131.0 million in 2022, then plummeted by 86.26% to $18.0 million in 2023, then plummeted by 166.67% to -$12.0 million in 2024, then soared by 1008.33% to $109.0 million in 2025.
  • Business Quant data shows Restructuring Costs for BSX at $109.0 million in Q4 2025, -$8.0 million in Q3 2025, and $83.0 million in Q2 2025.